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Objectives:  Pulmonary  sarcomatoid  carcinomas  (SC)  are  rare  tumors,  associated  with  worse  prognosis
and  resistant  to  platinum-based  regimens.  Therapies  targeting  the PD-1/PD-L1  pathway  are  an  emerging
treatment  for lung  cancer.  By  characterizing  intra-tumoral  immune  inﬁltration  and  evaluating  PD-L1
expression,  it  could  be  possible  to predict  the  efﬁcacy  of  these  new  treatments.
Materials  and  methods:  From  1997  to  2013,  data  from  all patients  with  SC  who  underwent  lung  resection
was  collected.  Tumor-immune  inﬁltration  and  PD-L1  expression  were  studied  by  immunochemistry  tests,
analyzing  CD3  (clone  SP7),  CD4  (clone  1F6),  CD8  (clone  C8/144b),  CD20  (clone  L26), CD163 (clone  10D6),
MPO  (clone  59A5),  and  PD-L1  (clone  5H1).  Results  were  compared  to those  of  54 NSCLC.
Results:  In  total, 75  SC  were  included.  Forty  (53%)  SC  expressed  PD-L1  vs  11  NSCLC  (20%)  (p  <  0.0001).
CD3+  tumor-inﬁltrating  lymphocytes  and  CD163+  tumor-associated  macrophages  were  more  important
in SC  than  in NSCLC  (median  23% [17–30]  of tumoral  surface  vs 17%  [7–27],  p  =  0.011  and  23%  [17–30]
vs  20%  [13–23],  p = 0.002, respectively).  In SC,  the presence  of Kirsten  Ras  (KRAS) mutations,  blood  ves-
sel  invasion,  and  TTF1+  positivity  were  associated  with PDL1  expression.  On  multivariate  analysis,  only
CD163+  macrophages  and blood-vessel  invasion  were  associated  with  tumoral  PD-L1 expression.  High
levels of  tumor-inﬁltrating  lymphocytes  (CD3+  or CD4+  and  not  CD8  +  ) constituted  a factor  of good  prog-
nosis  on survival.  Interestingly,  PD-L1  expression  distinguishes  subpopulations  within  tumor-inﬁltrating
lymphocytes  (CD3+  or CD4+)  with  different  prognosis
Conclusions:  PD-L1  expression  was  higher  in SC  than  in  NSCLC  as  well  as  immune-cell  inﬁltration  by
TCD3  cells  and  macrophages.  This suggests  that targeting  the PD-1/PD-L1  pathway  could  represent  a
new  potential  therapy.
©  2016  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CC. Introduction
Pulmonary sarcomatoid carcinomas (SC) are challenging to
anage. They probably arise from an epithelial clone withither squamous or glandular features [1]. These tumors share
ome similarities with non-small-cell lung cancer (NSCLC) in
erms of morphology and immunohistochemistry. They may
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c-nd/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
undergo a dedifferentiation process with the activation of an
epithelial-mesenchymal transition [2]. Their clinical presentation
is usually similar to that of NSCLC, with particularly strong associ-
ations observed with tobacco use, frequent atypical locations of
metastasis, such as in the peritoneum [3], and highly-prevalent
blood-vessel invasion [1]. The prognosis is poor, irrespective of the
stage of disease [3,4].
SC exhibit a large number of somatic mutations [5] that may
be related to tobacco use. These tumors present high levels of
chemoresistance to platinum-based regimens, with disease pro-
gression reported in two-thirds of patients on ﬁrst evaluation [3,6].
New targets must therefore be explored in order to improve the
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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(ig. 1. PD-L1 expression in patients with NSCLC and SC.
or  each tumor, PD-L1 expression is represented by a white (NSCLC) or a black circle
SC). P-value by Mann Withney test.
anagement of these tumors. Recently, MET  exon 14 splicing alter-
tions have been described in this histological subtype in patients
hat which should allow to treat some of these patients with anti-
ET  therapy [7,8].
We recently showed that these tumors exhibited high muta-
ion rates [5], suggesting a high amount of tumoral neoantigens,
hich should induce strong tumor immunogenicity. Rich inﬂam-
atory and immune inﬁltrates have been described in these tumors
9], usually consisting of neutrophils in giant-cell carcinomas and
ymphoplasmacytic cells in spindle-cell carcinomas, which could
rove the existence of a tumor immunoselection phenomenon.
ur goal was to investigate whether programmed cell death of
igand-1 (PD-L1) played a role in sarcomatoid sarcomas. PD-L1 is
verexpressed in certain tumors and induces a peripheral block-
de of T-cell immune response. In a previous report, Velcheti et al.
tudied PD-L1 expression using immunoﬂuorescence analysis in a
etrospective cohort involving 445 NSCLC cases and 13 SC. They
eported positive PD-L1 expression in 69.2% of the SC, compared
o 27.4% of the NSCLC cases (p <0.01) [10]. More recently, PD-L1
as expressed in 90% of a Korean cohort of 41 SC [11]. We  sought
o study PD-L1 expression and quantify tumor immune inﬁltra-
ion by macrophages, neutrophils, and T and B lymphocytes in 75
aucasian patients with SC and compared these ﬁndings to those
f a cohort of non-small cells lung cancers (NSCLC). We  also ana-
yzed the relevant factors associated with PD-L1 expression and
heir prognostic value.
. Material and methods
.1. Sarcomatoid cohort
From January 1995 to April 2013, we included all patients with
athologically-proven primary pulmonary SC based on surgical
ormalin-ﬁxed parafﬁn-embedded tissue samples (FFPE) (Depart-
ent of Pathology, Tumorothèque des Hôpitaux Universitaires de l’Est
arisien [the East Paris University Hospitals’ tumor biobank]). Their
istology was centrally reviewed (M.A.) and all the clinical data
nd molecular biomarker analyses (Kirsten Ras [KRAS], epidermal
rowth factor receptor [EGFR], anaplastic lymphoma kinase [ALK],
IK3CA, human epidermal growth factor receptor 2 [HER2], and
RAF) [1] were taken from previous publications, provided in Sup-
lementary Table 1.
Surgical samples were used to perform tissue micro-array anal-
sis, with 1.0 mm-diameter cores. All the tissue blocks from each
urgical specimen were reviewed (median of 26 blocks per case,
nterquartile range (Q1-Q3): 18–41). Core areas were selected with
he aims of collecting data on all the different morphological areas
i.e., epithelial, sarcomatous, and a mix  of both) from each tumor
supplementary Fig. 1). A median of four (Q1-Q3): (3–5) cores perer 98 (2016) 51–58
tumor were extracted. Surgical samples from consecutive NSCLC
tumors (arbitrary 20 adenocarcinomas, 19 squamous, and 15 large
cell carcinomas) were selected to be compared to the SC cohort.
Demographic characteristics did not differ from those of SC cohort
except for the age (Table 1 and Supplementary Table 2) with a
median of 61 years (53–69) for SC compared to 65 (60-45) for NSCLC
(P = 0.002). For NSCLC, 3–4 cores were selected from each tumor, 2
from the center and at least 1 from the periphery of the tumor.
According to national guidelines, each patient signed a research
consent form.
2.2. Analysis of PD-L1 expression
To measure PD-L1 expression, we  used a murine anti-B7-H1
(PD-L1) monoclonal antibody (clone 5H1) provided by Dr. Lieping
Chen (Yale University, New Haven, CT, USA). Brieﬂy, 3-m sections
were deparafﬁnized, rehydrated, and washed with phosphate-
buffered saline (PBS). The PD-L1 antigen was retrieved by means
of a tris-EDTA buffer (pH 9) (Dako, Courtaboeuf, France) for 40 min
(min) in a steamer. The samples were blocked for peroxidase
endogenous activity using the Dako Dual Endogenous and Serum-
free blocks, prior to incubation with the primary antibody (1/500
dilution) overnight at +4 ◦C. Ampliﬁcation was  performed using
the Dako EnVision anti-mouse immunoperoxidase method, with
diaminobenzidine as the chromogen, for the purposes of detection.
Irrelevant mouse IgG1 for mouse antibody (Dako) was used as the
negative control. Human placenta cores were included in the tissue
micro-array (TMA) as positive controls. PD-L1 tumor positivity was
deﬁned as ≥5% tumor cell membrane staining.
2.3. Analysis of immune-cell inﬁltration
To characterize immune-cell populations, immunohistochem-
istry studies were performed by means of a Benchmark System®
(Ventana medical system, Tucson, AZ, USA), using FFPE 3-m slides
to characterize T lymphocytes by CD3 (clone SP7; dilution: 1:200;
incubation: 20 min; Labvision, Fremont, CA, USA), CD4 (clone 1F6;
dilution: 1:25; incubation: 60 min; Novocastra, Nanterre, France),
CD8 (clone C8/144b; dilution: 1:50; incubation: 32 min, DAKO),
and CD20 (clone L26, dilution 1:400, 40 min, DAKO); macrophages
by CD163 (clone 10D6; dilution: 1:100; incubation: 32 min; Novo-
castra); and neutrophils by myeloperoxidase (MPO) (clone 59A5;
dilution: 1:100; incubation: 32 min; Novocastra). More details have
been provided in Supplementary Table 3. The mean percentage of
immune-positive cells per tumoral surface was evaluated for each
tumor sample.
2.4. Statistical analyses
Categorical variables were compared by means of chi-squared
or Fisher’s exact test. Non-normal continuous variables were
expressed as medians (interquartile). The Mann-Whitney U test
was used on non-normal continuous variables. For survival anal-
ysis, Cox test was used in univariate and multivariate analyses.
For logistic regression, independent variables exhibiting a p < 0.1
in the univariate analyses were included in the ﬁnal model, cho-
sen using a backward-stepwise variable elimination method based
on the p-value, as candidate predictors. Redundant variables were
not included in the ﬁnal model. Results were considered signiﬁ-
cant if the p value was <0.05. Statistical tests were performed using
SPSS 20.0 software (IBM Corporation, New York, NY, USA), and
graphs were constructed using Graphpad software (GraphpadInc,
San diego, CA, USA).
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Table  1
Factors associated with PD-L1 expression in univariate analyses in patients with SC (n = 75).
Factors Overalln = 75n (%) PDL1 (−)
n = 35
n
(%) PDL1 (+)
n  = 40
n (%)
Two-tailed
p-value*
Age 0.647
≤61years 39 (52) 17 (44) 22 (56)
>61years 36 (48) 18 (50) 18 (50)
Gender 0.412
Women  16 (21) 9(56) 7 (44)
Men  59 (79) 26 (44) 33 (56)
Tobacco use 1
Never 3 (4) 1(33) 2 (67)
Current/former 72 (96) 34 (47) 38 (53)
pT  0.362
1  7 (9) 5 (71) 2 (29
2  31 (41) 15 (48) 16 (52)
3  32 (43) 12 (38) 20 (63)
4  5 (7) 3 (60) 2 (40)
pN  0.359
N0  39 (52) 16 (41) 23 (59)
N+  36 (48) 19 (53) 17(47)
Stage 0.847
I  15 (20) 7 (47) 8 (53)
II  33 (44) 16 (48) 17 (52)
III  23 (31) 11 (48) 12 (52)
IV  4 (5) 1 (25) 3 (75)
Visceral-pleura invasion 0.169
Negative 34 (45) 19 (56) 15 (44)
Positive 41 (55) 16 (39) 25 (61)
Parietal-pleura invasion 0.057
Negative 57 (76) 30 (53) 27 (47)
Positive 18 (24) 5 (28) 13 (72)
Blood-vessel invasion 0.045
Negative 7 (9) 6 (86) 1 (14)
Positive 68 (91) 29 (43) 39 (57)
Histological subtype 0.01
Carcinosarcoma 9 (12) 8 (89) 1 (11)
Other  subtypes 66 (88) 27 (41) 39 (59)
Pleomorphic carcinoma 59 (79) 25 (42) 34 (58)
Giant-cell carcinoma 4 (5) 2 (50) 2 (50)
Spindle-cell carcinoma 1 (1) – 1 (100)
Spindle-cell carcinoma and giant-cell carcinoma 2 (3) – 2 (100)
TTF1  IHC 0.02
Negative 40 (53) 24(60) 16 (40)
Positive 35 (47) 11(31) 24 (69)
P63  IHC 0.0003
Negative 54 (72) 18(33) 36 (67)
Positive 21 (28) 17 (81) 4 (19)
KRAS  mutations 0.016
Wild  type 52 (69) 29 (56) 23 (44)
Mutated 23 (31) 6 (26) 17 (74)
EGFR mutations 1.0
Wild  type 71 (99) 35 (47) 39 (53)
Mutated 1 (1) – 1 (100)
PIK3CA  mutations 1.0
Wild  type 69 (92) 32 (46) 37 (54)
Mutated 6 (8) 3 (50) 3 (50)
p oid tr
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bT: pathological T stage; pN: pathological lymph node metastasis; TTF1 IHC: thyr
rowth factor receptor; PIK3CA: phosphatidylinositol-4, 5-bisphosphate 3-kinase, c
* Fischer’s exact or chi-squared test.
. Results
.1. Population characteristics
In total, 77 consecutive patients had pathologically-proven pri-
ary pulmonary sarcomatoid carcinoma, based on surgical FFPE
issue samples. All the patients were included in the study, except
wo for whom not enough tissue was available for testing. The
edian age was 61 years old (Q1–Q3, 53–69) (Table 1). Most
atients were males (79%) and smokers (96%). There were 15
atients presenting with Stage I (20%), 33 with Stage II (44%), 23
ith Stage III (31%), and four with Stage IV (5%) (adrenal gland: n = 1;
rain: n = 2; pleural nodule: n = 1). Pleomorphic carcinoma (79%)anscription factor-1 immunohistochemistry; KRAS: Kirsten Ras; EGFR: epidermal
ic subunit alpha.
was the most frequent subtype found, followed by carcinosarcoma
(12%). Blood-vessel invasion was found in 68 (91%) of the tumors.
The molecular biomarker analysis results were published, reveal-
ing KRAS mutations in 23 (31%) tumors, PIK3CA in six (8%), and
EGFR in one (1%).
3.2. Intratumoral PD-L1 expression
Membranous PD-L1 staining was  observed in tumor cells in 40
(53%) cases (Table 1). Distribution of PD-L1 expression in tumor
cells with a 5% of increments is given in Supplementary Fig. 2. In
27% of cases (n = 20/75), PD-L1 expression was  observed in both the
epithelial and sarcomatous areas, in 13% only in the sarcomatous
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Fig. 2. Intratumoral immune cell characterization.
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ells  (x400 magniﬁcation). B: intermediate levels of PD-L1 expression with interme
xpression with high inﬁltration by CD3 and CD163+ cells (×400 magniﬁcation).
reas (n = 10/75), and in 13% only (n = 10/75), in the epithelial areas.
D-L1 expression did not differ between the epithelial and sarco-
atoid components (p = 1.0, Fisher’s exact test). PD-L1 expression
as higher in SC than in NSCLC in which PD-L1 was expressed in
1 (20%) cases (p < 0.0001) 5/20 adenocarcinomas (25%), 3/19 squa-
ous carcinomas (16%), large cell carcinomas 3/15 (20%) (Fig. 1,
upplementary Table 2). PD-L1 could also be expressed by immune
ells as shown in Supplementary Fig. 2.
.3. Intratumoral immune-cell inﬁltration
Intratumoral immune-cell inﬁltration comprised a large inﬁl-
ration of CD3+ T-cells (tumoral surface median: 23%; (Q1–Q3):
17–30]) including CD8+ T-cells (9%; (Q1–Q3): [7–12]), and CD4+ T-
ells (10%; [5–14]). Large amounts of CD163+ macrophages (23%;
17–30]) were observed, though these were still fewer than the
umber of CD20 + B-cells (3.5%; [1–8]) and MPO+ neutrophils (5.5%;
2–11]) found (Supplementary Table 4).
Inﬁltration by T CD3+ cells and CD163+ macrophages were
igher in SC than in NSCLC (p = 0.011 and p = 0.002, respectively)
hile less TCD8+ and B CD20+ cells were observed (p = 0.0002 and
 = 0.03, respectively). Inﬁltration by TCD4+ T-cells and neutrophils
id not differ between SC and NSCLC (Table 2).
.4. Factors associated with PD-L1 expression
On univariate analysis, neither clinical factors, such as age,
ender or tobacco status, nor disease stage, i.e., tumor, node,
nd metastasis (TNM) classiﬁcation, tumor diameter or presence
f lymph-node metastasis, were associated with PD-L1 expres-
ion (Table 1). Blood-vessel invasion and TTF1 positivity were
igniﬁcantly associated with PD-L1 expression (Table 1). Of allnd CD163). A: no PD-L1 expression and almost no inﬁltration by CD3+ and CD163+
inﬁltration by CD3+ and CD163+ cells (×400 magniﬁcation). C: high levels of PD-L1
the molecular abnormalities tested, KRAS mutations were the
only ones associated with PD-L1 expression. Moreover, PD-L1+
tumors exhibited signiﬁcantly-higher inﬁltration of T CD8+ cells
and CD163+ macrophages compared to PD-L1- tumors, (10% vs. 8%,
p = 0.001 and 27% vs. 20% p = 0.002, respectively) (Supplementary
Table 4, Fig. 2).
In the ﬁnal logistic regression model, blood-vessel invasion and
CD163+ cell levels were signiﬁcant independent factors associ-
ated with PD-L1 expression (odds ratio [OR]: 17.05 [1.02–285.74],
p = 0.049 and 1.13 [1.05–1.22], p = 0.001, respectively). There was a
trend observed towards PD-L1 positivity with the presence of KRAS
mutations (OR: 3.3 [0.98–11.04], p = 0.053) (Table 3).
3.5. Survival analyses
In univariate analyses, pathological stage with T and N status,
parietal pleural invasion were associated with poorer overall sur-
vival (OS) and T CD3+ and T CD4+ cell inﬁltration with better OS
(Table 4). In multivariate analyses, T and N status, parietal pleural
invasion were associated with poorer OS and T CD4+ cell inﬁltration
with better OS (Table 4). PD-L1 expression did not inﬂuence overall
survival OS (Fig. 3, Table 4). Interestingly, PD-L1 expression dis-
tinguishes subpopulations within tumor-inﬁltrating lymphocytes
(CD3+ or CD4+) with different prognosis
4. Discussion
SC are associated with poor prognosis and high levels of
chemoresistance [3], underlining the necessity of ﬁnding new
potential therapy methods. Therapies targeting immune molecule
checkpoints could be particularly interesting in this indication.
In our study, we observed PD-L1 expression in 53% of the 75 SC
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Table  2
Intratumoral immune-cell characterization in patients with SC and NSCLC.
Factors SCn = 75Median (%) [IQR] NSCLCn = 54Median (%) [IQR] Two-tailed p-value*
% T CD3+ cells 23 [17–30] 17 [7–27] 0.011
%  T CD8+ cells 9 [7–12] 13 [8–20] 0.0002
%  T CD4+ cells 10 [5–14] 11 [7–17] 0.07
%  B CD20+ cells 4 [1–8] 6 [3–12] 0.032
%  Macrophage CD163+ cells 23 [17–30] 20 [13–23] 0.002
%  Neutrophil MPO+ cells 6 [2–11] 7 [3–12] 0.99
IQR: interquartile range; MPO: myeloperoxidase.
* Mann Whitney test.
Table 3
Factors associated with PDL1 expression in patients with SC on multivariate analysis (n = 75).
Factors OR (95% CI) Two tailed p-value*
Parietal-pleura invasion (+ vs. −) – >0.1
Blood-vessel invasion (+ vs. −) 17.05 [1.017–285.74] 0.049
Carcinosarcoma (no vs. yes) – >0.1
TTF1 (no vs. yes) – >0.1
KRAS mutations (mutated vs. wild type) 3.3 [0.98–11.04] 0.053
%  CD8+ cells – >0.1
%  CD 163+ cells 1.13 [1.05–1.22] 0.001
O Kirste
p
p
m
K
a
i
g
w
r
v
o
t
o
T
U
N
pR: odds ratio; CI: conﬁdence interval; TTF1: thyroid transcription factor-1; KRAS: 
* Logistic regression with backward elimination.
atients that was higher than the 20% observed in the NSCLC
atients. SC were also characterized by a strong CD3T cell and
acrophage inﬁltration compared to NSCLC. Blood-vessel invasion,
RAS mutations, and tumor CD163+ macrophage inﬁltration were
ll independently associated with PD-L1 expression. Lastly, tumor-
nﬁltrating CD3+ and CD4 +lymphocytes proved to be a factor of
ood prognosis.
We  found that 53% of patients with SC and 20% of patients
ith NSCLC exhibited positive PD-L1 expression, which is in the
ange of the usually reported values for NSCLC (20–60%). The large
ariety in PD-L1 positivity could be related to the heterogeneity
f technical requirements for measuring PD-L1 expression. Firstly,
he inter-study variations could be related to the different thresh-
lds of positivity used in each, as an optimal threshold has yet
able 4
nivariate and multivariate analyses of overall survival.a
Factors Univariate analysis 
HR (CI 95%) 
Clinical
Age (<61 vs. ≥61 years) 0.81 (0.46–1.45) 
Gender (female vs. male) 1.48 (0.75–2.92) 
Tobacco status (smoker/former vs. never) 0.88 (0.21–3.67) 
Pathological
Pleomorphic carcinomas vs. other subtypes 0.96 (0.20–4.7) 
Stage (I vs. stage II–III) 5 (2.14–11.7) 
Diameter (<5 vs. ≥5 cm)  2.29 (1.26–4.1) 
Lymph-node metastasis (N0 vs. N+) 2.20 (1.17–4.023) 
Blood  vessel invasion (no vs. yes) 1.94 (0.69–5.45) 
Lymphatic emboli (no vs. yes) 0.92 (0.82–1.03) 
Vascular emboli (no vs. yes) 0.944 (0.85–1.05) 
Visceral pleural invasion (no vs. yes) 1.67 (0.93–3.01) 
Parietal pleural invasion (no vs. yes) 2.42 (1.278–4.60) 
PD-L1 positive vs. negative 1.07 (0.60–2.00) 
CD3  (>20% vs ≤20%) 0.38 (0.21–0.69) 
CD8  (>9% vs ≤9%) 0.66 (0.35–1.21) 
CD4  (>10% vs ≤10%) 0.34 (0.17–0.69) 
CD20  (>4% vs ≤4%) 0.535 (0.284–1.005) 
CD163 (>23% vs ≤23%) 0.60 (0.33–1.10) 
MPO  (>5% vs ≤5%) 1.01 (0.57–1.79) 
S: not signiﬁcant.
a Analysis of 64 patients, 4 missing data, and 7 patients died in the 30 days after surger
* Cox’s model; independent variables with p < 0.1 in univariate analyses were included i
rocedure.n ras.
to be deﬁned. In line with other studies, we chose a threshold of
5%, while some have opted for 1% [12] or 10% or higher [13–17].
Secondly, inter-study variations could be related to the primary
antibody used. We  used clone 5H1, which was used in nivolumab
Phase I trials [18]. However, for the nivolumab Phase III trial, clone
28–8 (Epitomics, Burlingame, CA, USA) was  used [19]. The results of
PD-L1 expression measured by either E1L3N clone®(Cell signaling,
Saint Quentin, France) or clone 5H1 did not correlate [20]. Stromal
PD-L1 expression, measured with clone SP142® (Spring Bioscience,
Pleasanton, CA, USA), was predictive of response to anti-PD-L1 ther-
apy in the MPDL3280 Phase I clinical trial [21]. Clone 22C3 (Merck)
was used for the pembrolizumab Phase I study, demonstrating that
high levels of tumoral PD-L1 expression (>50%) were associated
with better response to anti-PD-L1 therapy [22].
Multivariate analysis
p* HR (CI 95%) p*
0.486
0.26
0.865
0.961
<0.0001
0.006 1.89 (0.99–3.62) 0.055
0.013 2.63 (1.35–5.12) 0.004
0.211
0.155
0.272
0.088
0.007 2.75 (1.31–5.78) 0.007
0.823
<0.0001 NS
0.132 NS
0.003 0.34 (0.16–0.72) 0.005
0.052
0.099
0.985
y were censored. HR: hazard ratio. An HR > 1 indicates a longer OS.
n the multivariate analysis; NS variables were retrieved by a step-by-step backward
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verall survival analyses adjusted for PD-L1 positivity (A); CD3 (B); and CD4 (C) bo
or  survival analysis.
PD-L1 expression has been reported to be heterogeneous within
 tumor [23,24]. We  cannot exclude that the tissue microarray
nalysis may  favor false negativity [24]. However, in light of this,
e chose to conduct a tissue microarray analysis with the aims
f collecting a large sample of all possible tumoral morphologi-
al features. For each tumor, a median of 26 blocks were reviewed
nd a median of four cores were tested. Expression levels did not
iffer between the epithelial and sarcomatoid components which
s different from the Korean cohort [11]. However, PD-L1 expres--L1 and CD3 (D) and both PD-L1 and CD4 (E). The Kaplan-Meyer method was  used
sion was  also really higher in this study, with 90% of positivity
in these patients. Several reasons could explain this discrepancy
such as the different primary antibody used, the ethnicity of the
patients and perhaps the histological subtypes of SC. Our cohort
comprised more carcinosarcomas- in which PD-L1 expression was
weak (Table 1)-than the Korean study.
Tumor PD-L1 expression was associated with KRAS mutations,
probably due to tobacco use. Interestingly, in the pembrolizumab
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hase I trial, treatment with the anti-PD-L1 antibody induced
igher tumor response rates in the KRAS-mutated cases [22].
Tumor PD-L1 expression was also associated with blood-vessel
nvasion. As reported by other studies [1,25], we  observed a high
revalence of blood-vessel invasion in these tumors, which could
e related to hypoxia [26,27]. Interestingly, PD-L1 expression has
een shown to be induced by HIF-1 [28].
Lastly, we demonstrated that PD-L1 was associated with CD163+
acrophages. Macrophages can express PD-L1 [21], as well as
ther immune inﬁltrating cells (Supplementary Fig. 3). We  cannot
xclude the possibility that this positive association was not due to
D-L1 expression in macrophages.
We  found there to be high immune-cell inﬁltration in these
umors, especially concerning tumor-inﬁltrating lymphocytes
D3+, at a median of 23% of the tumoral surface. High levels of
umor-inﬁltrating lymphocytes CD3+ and CD4+ constituted a fac-
or of good prognosis. Interestingly, PD-L1 for tumor-inﬁltrating
ymphocytes CD3+ or CD4+, distinguishes subpopulations with
ifferent prognosis. This could suggest that PDL1 expression is
ssociated with the exhaustion of lymphocytes and that PD-L1
ctivation is an adaptive method of tumor resistance to cytokine-
roducing tumor-inﬁltrating lymphocytes rather than an aberrant
ell signaling, for example, via PTEN loss or via activation of
he MEK/ERK signaling pathways [29] The presence of tumor-
nﬁltrating lymphocytes, as a marker of a preexisting immune
esponse, associated with positive PD-L1 expression, is currently
he best-known predictive factor of efﬁcacy of these therapies [21].
These results provide real justiﬁcation for the use of PD-L1 or
D-1 immunotherapy in this histological subtype [18,21].
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